News|Articles|June 3, 2025

Hematology Month in Review: May 2025

A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.

May was a slow month for hematology at HCPLive, with relative silence from the FDA and an even spread of trial successes and failures. NovelMed’s Ruxoprubart, a novel complement-targeting immunotherapy, showed efficacy for treating paroxysmal nocturnal hemoglobinuria (PNH) in interim results from its phase 2 trial. On the other hand, Prothena Corporation’s birtamimab failed to achieve its primary phase 3 endpoint for treating AL amyloidosis.